Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion

Johann Wolfgang Goethe University Hospital0 sites40 target enrollmentJanuary 2006

ConditionsRetinal Vein Occlusion

Interventionstriamcinolone and bevacizumab

Drugstriamcinolone and bevacizumab

Overview

Phase: Phase 3
Intervention: triamcinolone and bevacizumab
Conditions: Retinal Vein Occlusion
Sponsor: Johann Wolfgang Goethe University Hospital
Enrollment: 40
Primary Endpoint: BCVA
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The aim of this pilot study was to investigate the effects of an intravitreal combination therapy using triamcinolone and bevacizumab in patients with retinal vein occlusion (RVO).

Detailed Description

This prospective study of a case series was conducted in 47 patients (n = 47 eyes; f/m: 21/26; mean age: 66.6 years) with ischemic central RVO (CRVO) (n = 15), non-ischemic CRVO (n = 7), or branch RVO (BRVO) (n = 25). A core pars plana vitrectomy with aspiration of 1.5 ml vitreous and infusion of balanced salt solution (BSS; 1 ml), 8 mg (0.4 ml) triamcinolone, and 1.25 mg (0.1 ml) bevacizumab was performed with a single sutureless sclerotomy and a 23 gauge probe tip. At baseline and follow-up, the best corrected visual acuity (BCVA; 6 m Snellen), and intraocular pressure (IOP; Goldmann tonometry), and central macular thickness (optical coherence tomography) were determined. In addition, the need for further treatment and adverse events were monitored.

Registry

clinicaltrials.gov

Start Date

January 2006

End Date

November 2008

Last Updated

13 years ago

Study Type

Interventional

Study Design

Single Group